MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Metastatic uveal melanoma (mUM) presents a poor prognosis with limited treatment avenues.
• MEK inhibitors (MEKi) like selumetinib show promise in improving progression-free survival in mUM.
• Immune checkpoint inhibitors (anti-PD-1) have demonstrated some efficacy in mUM.

Purpose of the Study:

• To evaluate the safety and efficacy of combining MEK inhibitors (MEKi) with anti-programmed cell death-1 (anti-PD-1) therapy in mUM patients.
• To explore a potential synergistic treatment strategy based on findings in metastatic cutaneous melanoma.
• To report clinical experience with this combination in patients lacking alternative treatments.

Main Methods:

• Case series reporting on three patients with mUM treated with a combination of MEKi and anti-PD-1 therapy.
• Clinical observation of treatment response and adverse events.
• Assessment of efficacy and toxicity profiles.

Main Results:

• Treatment efficacy was challenging to assess due to the early onset of severe toxicities.
• Observed severe adverse events included pneumonitis and Takotsubo syndrome.
• The combination therapy necessitated careful monitoring due to significant toxicity concerns.

Conclusions:

• The combination of MEKi and anti-PD-1 therapy in mUM was associated with severe early toxicities.
• Further investigation into the safety and efficacy of this combination is warranted.
• This case series underscores the need for careful evaluation of novel treatment strategies for mUM.